

COMPUGEN LTD  
Form 6-K  
April 22, 2004

**FORM 6-K**  
**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Report of Foreign Private Issuer**

Pursuant to rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934  
for the month of February 2004

Compugen Ltd.

(Translation of registrant's name in English)

72 Pinchas Rosen Street, Tel-Aviv 69512, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

On April 21<sup>st</sup>, 2004 Compugen Ltd. (the "Registrant") issued a Press Release, filed as Exhibit 1 to this Report on Form 6-K, which is hereby incorporated by reference herein.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Compugen Ltd.

(Registrant)

By: /s/ Mor Amitai

Title: President & CEO

Date: April 22<sup>nd</sup>, 2004

**Exhibit 1**

## **Compugen Reports First Quarter 2004 Financial Results**

**TEL AVIV, ISRAEL, April 21, 2004** - Compugen Ltd. (NASDAQ: CGEN) today reported financial results for the first quarter ended March 31, 2004.

Revenues for the quarter were \$1.5 million (including \$401,000 from research and development grants), compared to \$2.6 million (including \$455,000 from research and development grants) for the first quarter of 2003. The reduced revenues for the current period result primarily from the implementation of the previously disclosed plan to divest certain product lines in order to focus more of the Company's efforts on discovery based activities and its emerging therapeutic protein pipeline. The net loss for the quarter was \$3 million (including a non-cash charge of \$238,000 for amortization of deferred compensation), or \$0.11 per share, compared with a net loss of \$2.3 million (including \$94,000 of deferred compensation), or \$0.09 per share, for the corresponding quarter of 2003.

As of March 31, 2004, Compugen had \$58.1 million in cash, cash equivalents, and marketable securities, a decrease of \$2.4 million from December 31, 2003. The Company maintains its previous guidance of cash and cash related accounts decrease of \$15 to \$17 million for calendar 2004, resulting in an anticipated balance at year-end of approximately \$45 million.

"Our announcement during the past quarter of our discovery of several naturally occurring soluble splice variants of CD40 is another excellent example of the power of our predictive approach to research, and our discovery engines. In general, soluble proteins have inherent advantages for development as drugs," stated Mor Amitai, Ph.D., Compugen's President and Chief Executive Officer. "Blocking the CD40 pathway has been shown by others to effectively prevent rejection in organ transplantation and treat a variety of autoimmune diseases. Therefore, this is an extremely active field of research with a number of major biotechnology and pharmaceutical companies having development programs based on antibodies for the known, membrane-bound, CD40 ligand. Furthermore, we were very pleased last week to be notified of the granting of the first U.S. patent covering one of our novel CD40 variants," Dr. Amitai continued.

**Conference Call and Web Cast Information**

Compugen will hold a conference call to discuss its first quarter results on April 21, 2004 at 10:00 am EST. To access the conference call, please dial 1-866-500-4953 or 1-866-500-4964 from the US or +972-3-925-5910 internationally. A replay of the conference call will also be available approximately two hours after the completion of the live conference call. To access the replay, please dial +972-3-925-5901. The replay will be available until 12 noon EST on April 23, 2004.

The call will also be available via live Web cast through Compugen`s Website, located at [www.cgen.com](http://www.cgen.com).

## **About Compugen**

Compugen, a genomics-based drug and diagnostic discovery company, increases the probability of successful development of novel drug and diagnostic products by incorporating ideas and methods from mathematics, computer science, and physics into the disciplines of biology, organic chemistry, and medicine. This unique capability results in powerful predictive models and discovery engines, which are both advancing the understanding of important biological phenomena and enabling the discovery of numerous potential therapeutic products and diagnostic markers. The Company has an early-stage in-house pipeline consisting of selected therapeutic protein candidates discovered by the Company; additional discoveries have been out-licensed for development. Among Compugen's customers and partners are leading pharmaceutical and diagnostic companies, such as Abbott Laboratories, Diagnostic Products Corporation, Novartis, and Pfizer. For additional information, please visit Compugen's updated corporate Website at [www.cgen.com](http://www.cgen.com).

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words like "may," "expects," "believes," and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to the development of new products; the ability to implement technological improvements; the ability of Compugen to obtain and retain customers. These and other factors are identified and more fully explained under the heading "Risk Factors" in Compugen's annual reports filed with the Securities and Exchange Commission.

### ***Company contact:***

Nurit Benjamini

Chief Financial Officer

Compugen Ltd.

Email: [nurit@cgen.com](mailto:nurit@cgen.com)

Tel: +972-3-7658-525

**COMPUGEN LTD.**  
**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**  
(U.S. dollars in thousands, except for share and per-share amounts)

|  | Three Months Ended |                |
|--|--------------------|----------------|
|  | March 31,<br>2004  | 2003           |
|  | Unaudited          | Unaudited      |
| <b>Revenues</b>  |                    |                |
| Products and services                                  | 1,119              | 2,120          |
| Research and development grants                        | 401                | 455            |
| <b>Total revenues</b>                                  | <b>1,520</b>       | <b>2,575</b>   |
| <b>Cost and Expenses</b>                               |                    |                |
| Cost of products and services                          | 464                | 616            |
| Research and development expenses                      | 2,896              | 3,168          |
| Sales and marketing expenses                           | 678                | 1,025          |
| General and administrative expenses                    | 787                | 713            |
| Amortization of deferred compensation                  | 238                | 94             |
| Total operating expenses                               | 5,063              | 5,616          |
| <b>Operating loss</b>                                  | <b>(3,543)</b>     | <b>(3,041)</b> |
| Financing income, net                                  | 460                | 703            |
| Other income   | 93                 | -              |
| <b>Net loss</b>  | <b>(2,990)</b>     | <b>(2,338)</b> |
| Basic and diluted net loss per ordinary share          | (0.11)             | (0.09)         |
| Weighted average number of ordinary shares outstanding | 27,198,759         | 26,162,955     |

**COMPUGEN LTD.**  
**CONDENSED CONSOLIDATED BALANCE SHEETS DATA**  
(U.S. dollars, in thousands)

|   | March 31,<br><u>2004</u> | December 31,<br><u>2003</u> |
|---|--------------------------|-----------------------------|
|   | Unaudited                | Audited                     |
| <b>ASSETS</b>   |                          |                             |
| <b>Current assets</b>   |                          |                             |
| Cash, cash equivalents, short-term cash deposits, and marketable securities | 20,097                   | 16,707                      |
| Receivables and prepaid expenses  | 1,442                    | 1,401                       |
| <b>Total current assets</b>   | <b>21,539</b>            | <b>18,108</b>               |
| <b>Long-term investments</b>  |                          |                             |
| Marketable securities   | 38,008                   | 43,803                      |
| Other assets  | 1,595                    | 1,678                       |
| <b>Property and equipment, net</b>  | <b>3,625</b>             | <b>3,937</b>                |
| <b>Total assets</b>   | <b>64,767</b>            | <b>67,526</b>               |
| <b>LIABILITIES AND SHAREHOLDERS` EQUITY</b>                                 |                          |                             |
| <b>Current liabilities</b>  |                          |                             |
| Accounts payable and accrued expenses                                       | 2,404                    | 3,629                       |
| Deferred revenues   | 946                      | 1,566                       |
| <b>Total current liabilities</b>  | <b>3,350</b>             | <b>5,195</b>                |
| <b>Long-term liabilities</b>  |                          |                             |
| Accrued severance pay   | 1,976                    | 1,997                       |
| Other long-term liabilities   | 60                       | 60                          |
| Investment in Evogene   | 466                      | 466                         |
| <b>Total long-term liabilities</b>  | <b>2,502</b>             | <b>2,523</b>                |
| <b>Total shareholders` equity</b>   | <b>58,915</b>            | <b>59,808</b>               |
| <b>Total liabilities and shareholders` equity</b>                           | <b>64,767</b>            | <b>67,526</b>               |